Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. It offers generic pharmaceutical products in various dosage forms, including tablets, capsules, ointments, creams, liquids, injectables, and inhalants; and provides basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances. Its principal branded pharmaceutical products comprise Copaxone for multiple sclerosis; Provigil and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder; Azilect for the treatment of Parkinsonĺs disease; Fentora and Actiq for the treatment of pain in opioid-tolerant adult patients with cancer; Amrix for muscle spasm in acute, painful, musculoskeletal conditions; ProAir for the treatment of bronchial spasms; and Qvar for long-term control of chronic bronchial asthma. The company also offers Treanda for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkinĺs lymphoma; Tevagrastim/Ratiograstim that stimulate the production of white blood cells; Eporatio, which stimulates the production of red blood cells; Plan B One-Step for emergency contraception; ParaGard, a non hormonal intrauterine contraceptive; hormone therapy treatments for menopause/perimenopause; and therapies for infertility and urinary incontinence. In addition, it produces active pharmaceutical ingredients in the areas of respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company offers animal health products; and distributes third party products. It has co-operation agreements with Lonza Group Ltd. for biologic pharmaceuticals; and OncoGenex Pharmaceuticals, Inc. for OGX-011. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.